{"id":"W4386329445","doi":"10.1186/s13058-023-01701-9","title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Hazard ratio; Internal medicine; Breast cancer; Oncology; Population; Cancer; Placebo; Letrozole; Progression-free survival; Proportional hazards model; Chemotherapy; Tamoxifen; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001766812,0.0006715275,0.001118086,0.0004690312,0.0005214753,0.0001486669,0.0008528261,0.0002545236,0.002981146],"category_scores_gemma":[0.0000915862,0.0004697809,0.0001154485,0.003115908,0.000699996,0.0005356787,0.0003650176,0.001882695,0.0001135402],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00360708,"about_ca_system_score_gemma":0.002560737,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03060491,"about_ca_topic_score_gemma":0.0171582,"domain_scores_codex":[0.9922765,0.0005690175,0.0008161444,0.001402591,0.002522255,0.002413492],"domain_scores_gemma":[0.9963138,0.0008754706,0.0002320138,0.001165801,0.000803311,0.0006096514],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7230954,0.0009495901,0.05962095,0.0002934882,0.001533953,0.001060465,0.00653302,0.01463279,0.01403774,0.0001337145,0.001692481,0.1764164],"study_design_scores_gemma":[0.1049393,0.001253867,0.8776325,0.001638282,0.00008797258,0.000246681,0.002729259,0.0007799856,0.0002851211,0.0006815232,0.008910979,0.0008144949],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9582652,0.001291073,0.00001914105,0.03346757,0.0005968414,0.002782013,0.003028575,0.0003321259,0.0002174161],"genre_scores_gemma":[0.9895198,0.002032418,0.0001062101,0.0005598044,0.002208387,0.003325676,0.0002962399,0.0002563514,0.001695146],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8180115,"threshold_uncertainty_score":0.9997754,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05336560724581937,"score_gpt":0.374452246573516,"score_spread":0.3210866393276967,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}